Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Dec 15 | 2023Could Abecma and Carvykti Be Approved in January 2024? Obe-cel MAA Could Happen in Q1 2024; December CHMP HighlightsAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Dec 14 | 2023Uncertainty around OS Benefit Induced by Abecma in 3 – 5L MM; A MAIC Analysis Supports Carvykti’s Superiority versus Abecma in Early Line MM; ASH 2023 Analysis 7Access Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Dec 14 | 2023Anito-cel Elicits Improved Responses Across HR Subgroups; Gracell’s GC012F Shows Best-In-Class Safety and Efficacy Profiles; Increased Lymphodepleting Dose Enhances P-BCMA-ALLO1's Responses Significantly; ASH 2023 Analysis 6Access Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 Dec 14 | 2023A New Pivotal Trial for Caribou’s CB-010 in ≥2L LBCL to Start in 2024; Is the FDA Changing Perspective on the Clinical Development of Allogeneic CAR-Ts in Earlier Lines?Access Free BlastFree
Posted in: Autologous, CD19 Dec 13 | 2023JNJ / AbelZeta and Mustang Bio Present Clinical Updates from their Assets Targeting CD20 in NHL; ASH 2023 Analysis 5Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Dec 13 | 2023Breyanzi Demonstrates Excellent Efficacy in 2L HR FL; Galapagos’s Point-of-Care Manufactured GLPG5101 Shows a Promising Efficacy and Safety Profile; ASH 2023 Analysis 4Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Dec 12 | 2023Breyanzi Demonstrates Long Duration of Response in 2L Transplant Ineligible LBCL and Consistent RW Results Regardless of Comorbidities in R/R LBCL; Prior Bridging Therapy Does Not Impact Yescarta Efficacy or Safety in R/R LBCL; ASH 2023 Analysis 3Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Dec 11 | 2023Obe-cel Demonstrates Promising Efficacy in Patients with Low Leukemia Burden; Pooled Analysis from ALLCAR19 and FELIX Trials Suggests Long Durability of Response; ASH 2023 Analysis 2Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Dec 11 | 2023Could Carvykti Receive a Positive Opinion this Week? The Obe-cel Accelerate Assessment to Be Discussed for Adoption; December’s CHMP AgendaAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Dec 10 | 2023BMS-986393 Continues Showing Impressive ORR in ≥4L MM but Durability Fails to Impress; Initial Promising Results from AUTO8 in r/r MM; ASH 2023 Analysis 1Access Free Blast
Free
Posted in: Autologous, TCR Dec 07 | 2023Adaptimmune Completes Afami-cel Rolling BLA Submission in Advanced SSAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Nov 29 | 2023Novartis to Rapidly Advance YTB323 in Autoimmune Diseases; Cell Therapy Evaluation in MS Could Be Initiated Soon; Novartis’s R&D Day SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Nov 28 | 2023Autolus Submits Obe-cel BLA in R/R B-ALL; GC012F Receives IND Clearance in rSLEAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, Topics Nov 21 | 2023Abecma sBLA to Face FDA AdCom; PDUFA Date Delayed; Could Carvykti Be Approved Before Abecma in Earlier Lines of MM?Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Nov 21 | 2023CARTITUDE-6 to Start Recruiting Soon in the US; Legend’s Facility in Belgium Set to Start Clinical Trial Manufacturing; Legend’s Q3 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Nov 16 | 2023Thoughts on the Expansion of Arcellx and Gilead Partnership; Gilead to Expand Scope of CART-ddBCMA to Lymphomas and Exercise Option to ACLX-001Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, TCR Nov 15 | 2023Abecma Revenue Decreases Significantly; bbT4015 IND on Track for YE 2023; JW Tx to Initiate JWTCR001’s IIT by YE 2023; 2seventy Bio’s Q3 2023 Earnings CallAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Nov 14 | 2023GC012F's US Trial in MM Initiates Dosing; GC012F IND in SLE on Track for 2023; Gracell Initiates GC506 Clinical Development in Solid Tumors and Deprioritizes GC007g in B-ALL; Gracell’s Q3 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T Nov 14 | 2023Thoughts on Novartis’s Agreement with LegendAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T Nov 13 | 2023Roche Collaboration Milestones and Payments Accelerated; P-MUC1C-ALLO1's Clinical Update Postponed to H1 2024; Poseida’s Q3 2023 Earnings SummaryAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.